new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 agonists approved for clinical
Description
GLP-1RAs have been shown to reduce the levels of systemic inflammatory markers
The same pathways are being targeted, the same receptors activated, and in many cases the same drugs are being used
It may provide an alternative option if approved
Microglia function in the central nervous system during health and neurodegeneration
In HF, the heart loses its metabolic adaptability, which throws energy metabolism into disarray
doi: 10.1161/CIRCULATIONAHA.120.047965
